254 related articles for article (PubMed ID: 32581056)
1. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
[TBL] [Abstract][Full Text] [Related]
2. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Chen D; Barsoumian HB; Yang L; Younes AI; Verma V; Hu Y; Menon H; Wasley M; Masropour F; Mosaffa S; Ozgen T; Klein K; Cortez MA; Welsh JW
Cancer Immunol Res; 2020 Jul; 8(7):883-894. PubMed ID: 32299915
[TBL] [Abstract][Full Text] [Related]
3. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
4. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
5. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
6. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
7. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
8. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
10. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
11. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
12. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW; Yuca E; Scott SS; Zhao M; Paez Arango N; Cruz Pico CX; Saridogan T; Shariati M; Class CA; Bristow CA; Vellano CP; Zheng X; Gonzalez-Angulo AM; Su X; Tapia C; Chen K; Akcakanat A; Lim B; Tripathy D; Yap TA; Francesco MED; Draetta GF; Jones P; Heffernan TP; Marszalek JR; Meric-Bernstam F
Cancer Res; 2021 Nov; 81(21):5572-5581. PubMed ID: 34518211
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
16. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
17. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
18. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.
Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Ebstein S; Cortez C; Lowy I; Murphy AJ; Sleeman MA; Skokos D
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33837124
[TBL] [Abstract][Full Text] [Related]
19. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens.
Grimaldi A; Cammarata I; Martire C; Focaccetti C; Piconese S; Buccilli M; Mancone C; Buzzacchino F; Berrios JRG; D'Alessandris N; Tomao S; Giangaspero F; Paroli M; Caccavale R; Spinelli GP; Girelli G; Peruzzi G; Nisticò P; Spada S; Panetta M; Letizia Cecere F; Visca P; Facciolo F; Longo F; Barnaba V
Commun Biol; 2020 Feb; 3(1):85. PubMed ID: 32099064
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]